Difference between revisions of "NET of unknown primary"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
m (→Guidelines) |
||
| Line 12: | Line 12: | ||
=Guidelines= | =Guidelines= | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
| − | *[http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | + | *'''2015:''' [http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/26314775 PubMed] |
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
Revision as of 14:49, 27 March 2018
0 regimens on this page
0 variants on this page
|
Guidelines
ESMO
- 2015: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
All lines of therapy
- Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
- Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.